Dr. Babu is a board-certified neurologist and neuromuscular specialist and serve as a Physician Investigator at Massachusetts General Hospital (MGH), and as Instructor in Neurology at Harvard Medical School. Her career goal is to develop innovative molecular outcome measures to determine target engagement and dose-selection in early phase II clinical trials in Amyotrophic Lateral Sclerosis (ALS). ALS is a fatal disease with a huge unmet need for effective disease modifying therapeutic options and reliable molecular, imaging and electrophysiological outcome measures for patient stratification and measuring treatment responses in clinical trials. She has over 6 years of hands-on experience in diagnosing and treating motor neuron disease patients. She serves as the site principal investigator for several multi-center Phase I, II and III clinical trials in ALS.
She contributes to ALS research in a highly resourceful and multi-disciplinary collaborative environment at the Sean M Healy & AMG Center for ALS at MGH, in close collaboration with global leaders in the field of ALS research.
She has extensive training in clinical and translational research, including a Masters in Public Health (University of Maryland School of Public Health), Clinical and Translational Research Academy certificate program (Harvard Medical school), and the NIH-NINDS clinical trials methodology course. She has over five years of post-medical degree clinical and translational research experience at MGH (2016-Present), as well as previously at Cleveland Clinic Foundation (2011-2015) and University of Maryland School of Public Health (2006-2009).